Antigenics LLC is a Delaware limited liability company and a wholly-owned subsidiary of Agenus Inc. (NASDAQ: AGEN), a clinical-stage biotechnology company headquartered in Lexington, Massachusetts, United States. Originally formed in 1994 as Antigenics L.L.C., the entity has evolved through corporate restructuring while retaining its focus on key adjuvant technologies.
The company's core asset is the QS-21 Stimulon adjuvant, a saponin-based immunostimulant purified from the bark of the Quillaja saponaria tree. This adjuvant enhances both antibody-mediated and cellular immune responses, making it particularly effective in vaccine formulations for older adults or challenging pathogens. It serves as a critical component in GSK's AS01 adjuvant system.
Through longstanding licensing and supply agreements, Antigenics LLC has enabled the use of QS-21 Stimulon in multiple GSK vaccines, including the approved Shingrix recombinant zoster vaccine for shingles prevention and candidates for malaria and respiratory syncytial virus. The technology has been studied in dozens of clinical programs across infectious diseases and oncology.
Antigenics LLC operates within the United States as part of the Agenus group, which also includes subsidiaries focused on checkpoint antibodies, cell therapies, and sustainable adjuvant manufacturing via SaponiQx. Some royalty streams associated with GSK products have been monetized through financial transactions. In the broader vaccine adjuvant industry, the company holds a prominent position as the originator and primary licensor of this potent, widely adopted saponin technology.
Also known as Antigenics Inc., Antigenics L.L.C., and Agenus subsidiary.
Ready-to-use syringe replaces two-vial format, simplifying administration for clinicians; approval based on technical comparability and keeps same indication and dosing.
